1. Medicine

Category Archives: Medicine

US Orthopedic Soft Tissue and Sports Medicine Market

Posted on by

NEW YORK, July 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

US Orthopedic Soft Tissue and Sports Medicine Market

http://www.reportlinker.com/p01498091/US-Orthopedic-Soft-Tissue-and-Sports-Medicine-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

In 2012, the U.S. market for orthopedic soft tissue repair exceeded $1.5 billion.The orthopedic soft tissue repair market in the U.S. consists of anterior and posterior cruciate ligament (ACL/PCL) reconstruction and fixation products, cartilage repair therapies, meniscal repair devices, rotator cuff repair devices, shoulder and labrum repair devices, rotator cuff graft reinforcement devices, hip arthroscopy devices and biceps tenodesis devices. As the economy began to recover in the last quarter of 2010, residual demand boosted procedure volumes. Most of the segments in the orthopedic soft tissue repair market will be affected by the rising number of arthroscopies being performed at ambulatory surgery centers (ASCs), which will limit ASP growth. These physician-owned centers receive less reimbursement than hospitals and are more cost-conscious as a result. This limits price increases to some degree in all market segments. With the emergence of new health care legislation, pricing should stabilize as companies adjust.

Scope: This report pertains to a forecast period of 10 years (2009 2019) for the U.S.

Report Contents: Competitor Analysis Identified Strategic Opportunities Market Overview by Segment Trend Analysis by Segment Market Drivers & Limiters Mergers & Acquisitions Customer Feedback and Market Monitoring

Main Segments Included: ACL/PCL Reconstruction Market ACL/PCL Fixation Device Market Cartilage Repair Market Meniscal Repair Market Rotator Cuff Repair Market Shoulder Labrum Repair Market Rotator Cuff Graft Reinforcement Device Market Hip Arthroscopy Market Biceps Tenodesis Repair Market

Sub-Segments Included: Bone-Patellar Tendon-Bone Allografted Tendons Tibial Fixation Market Femoral Fixation Market Osteochondral Allograft Transfer Autologous Chondrocyte Implantation (ACI) Meniscal Allograft Transplantation Suture Meniscal Repair Market Implant Meniscal Repair Market Hybrid Meniscal Repair Market PLA Resorbable Suture Anchor Market Biocomposite Suture Anchor Market PEEK Suture Anchor Market Metal Suture Anchor Market All-Suture Anchor Market PEEK CF Suture Anchor Market Hip Radiofrequency Probe Market Banana Blade Market Hip Access Kit Market Suture Anchor Market Disposable Suture Passer Market Tenodesis Screw Market

Companies Included: DePuy Mitek MTF Cayenne Medical Tornier Parcus Medical Arthrex Zimmer MedShape Smith & Nephew Genzyme Allosource Biomet ConMed Linvatec RTI Biologics Stryker Wright Medical LifeNet Health Arthrocare Joint Restoration Foundation CTS KFx Medical University of Miami Tissue Bank Covidien

Others Include: LifeLink, Synovis Surgical Innovations, Various Tissue Banks.

Read the original post:

US Orthopedic Soft Tissue and Sports Medicine Market

Your medicine may have been banned globally

Posted on by

Be alert before taking a medicine. The one you are about to pop could be facing a global ban.

Several medicines for pain, fever, constipation, diarrhoea, or depression face a ban in developed countries like the US, EU, Japan and Australia. Even small countries like Bangladesh, Sri Lanka, Nepal have banned some.

Though allowed for sale by Indian regulatory authorities, the fact that other countries have found their side-effects to be worrisome, and prohibited their sale; implies patients and doctors should be cautious.

Experts say medicines get banned if their side-effects outweigh their benefits.

Every medicine has some side-effects. But once the side-effects prove dangerous, regulatory systems in the developed world impose a ban, says Dr CM Gulhati, editor of monthly index of medical specialities (MIMS), a medical journal for doctors.

Though the Ministry of Health and Family Welfare has been talking about executing a prohibition in India on medicines facing a global ban, nothing much seems to have taken shape.

The regulatory authorities here are weak. Unlike those in EU and US, says Dr Gopal Dabade, from the All India Drug Action Network (AIDAN).

Impact on patients Since globally banned medicines are permitted in India, patients tend to suffer most, say doctors. Often doctors are unaware of harmful side-effects, nor the global ban, and end up prescribing such medicines for their patients, says Dr Gulhati.

Then there is this tendency to self-medicate on part of patients that can prove hazardous.

K Raghu, a marketing professional in Basaveswarnagar, has used the medicine nimesulide in the past to relieve himself of fever.

Read the rest here:

Your medicine may have been banned globally

Human Genome Project : Nanotech and Microchip Precision Medicine (Jun 27, 2013) – Video

Posted on by


Human Genome Project : Nanotech and Microchip Precision Medicine (Jun 27, 2013)
SOURCE: http://www.cbsnews.com News Articles: Computers That You Eat (or That Eat You?) http://bigthink.com/endless-innovation/computers-that-you-eat-or-that...

By: SignsofThyComing

See the article here:

Human Genome Project : Nanotech and Microchip Precision Medicine (Jun 27, 2013) - Video

What is Health? How to be Healthy, Does Modern Medicine Work? Are Meds Safe? | The Truth Talks – Video

Posted on by


What is Health? How to be Healthy, Does Modern Medicine Work? Are Meds Safe? | The Truth Talks
Friend us!! http://www.Facebook.com/psychetruth What is Health? How to be Healthy, Does Medication Work? Are Meds Safe? Wellness | The Truth Talks Psychetrut...

By: psychetruth

Go here to see the original:

What is Health? How to be Healthy, Does Modern Medicine Work? Are Meds Safe? | The Truth Talks - Video

Sarah Cannon Research Institute And AstraZeneca Announce Personalized Medicine Partnership and Enhanced Strategic …

Posted on by

NASHVILLE, Tenn. & WILMINGTON, Del.--(BUSINESS WIRE)--

Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced today a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy.

Through our research, we know how vital and impactful individualized treatment options are for patients battling this complex disease, said Dee Anna Smith, chief executive officer of SCRI. By partnering with AstraZeneca, we are expanding opportunities to accelerate drug development and deliver more targeted therapies to patients who urgently need them.

Under the agreement, SCRI will work with AstraZeneca to identify potential patients for clinical trials and help explore biomarkers that predict response to specific treatments. In addition, SCRIs enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight, and operational contract research organization (CRO) trial management for early phase clinical development of multiple oncology compounds.

Building upon this unique collaboration with SCRI allows us to continue honing our capabilities to deliver high quality research in a timely and cost-effective manner, said Vice President of Early Clinical Development for AstraZeneca, Professor Andrew Hughes. Through this cutting-edge program design, we can rapidly and effectively implement clinical trials with greater access to a network of cancer patients for enrollment.

AstraZeneca is one of the initial participants in SCRIs molecular profiling program, which is part of Sarah Cannons broader personalized medicine initiative across the United States and United Kingdom. SCRI and AstraZeneca originally entered into an agreement to develop novel oncology compounds in 2010.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit us onsarahcannonresearch.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com.

See the original post here:

Sarah Cannon Research Institute And AstraZeneca Announce Personalized Medicine Partnership and Enhanced Strategic ...

AMSSM Sports Medicine Conference in Haiti to Advance Athletic Care by Teaching the Teacher

Posted on by

Newswise Port-au-Prince, Haiti Seven members of the American Medical Society for Sports Medicine (AMSSM) are in Haiti this week to provide sports medicine education for nearly 300 physicians, medical students, athletic trainers and first responders.

In partnership with the Haitian Sports Medicine Society (SHAMS), the AMSSM will host its first Sports Medicine/Sports Trauma and Event Medicine Conference in Haiti on June 29 July 3, 2013. The conference is designed as a teach-the-teacher course with the goal of advancing the education of professionals in Haiti who care for active people, from the professional athlete to the weekend warrior.

Led by Dr. Thomas Trojian, Chair of AMSSMs International and Inter-Organizational Relations Committee, the project is an AMSSM humanitarian initiative to reach out to sports medicine societies in underserved areas of the world to promote healthy lifestyles and heal people from athletic injuries.

AMSSM is interested in promoting the health of athletic people here in the United States and throughout the world and that is one of the reasons we decided to do this, Dr. Trojian said. If we can equip the physicians, trainers and first responders in Haiti with the tools and skills needed to improve athletic care of their patients, we will have succeeded.

The conference is divided into four components: 1) demonstrations of musculoskeletal ultrasound-guided and surgical procedures; 2) an Introduction to Sports Medicine course for medical students; 3) lectures on topics requested by members of SHAMS such as concussion, sideline management and pre-participation screenings for cardiac issues; and 4) clinical time spent with Haitian physicians treating patients.

In addition to AMSSM members, an orthopedic surgeon from the American Orthopaedic Society for Sports Medicine (AOSSM) and a neurologist from the American Academy of Neurology (AAN) will be joining the volunteer faculty.

AMSSM gratefully acknowledges SonoSite, Inc. for lending an ultrasound machine, SAM Medical Products for providing splints and the AMSSM Foundation for the shipment of 100 sports medicine books to Haiti.

About the AMSSM: The AMSSM is a multi-disciplinary organization of sports medicine physicians whose members are dedicated to education, research, advocacy and the care of athletes of all ages. Founded in 1991, the AMSSM now comprises more than 2,300 sports medicine physicians whose goal is to provide a link between the rapidly expanding core of knowledge related to sports medicine and its application to patients in a clinical setting. http://www.amssm.org

View post:

AMSSM Sports Medicine Conference in Haiti to Advance Athletic Care by Teaching the Teacher

Mariell Jessup, MD, Penn Medicine Cardiologist, Becomes President of the American Heart Association

Posted on by

PHILADELPHIA Mariell Jessup, MD, professor of Medicine, associate chief, Clinical Affairs, Division of Cardiovascular Medicine, and medical director of the Penn Medicine Heart and Vascular Center, has become the president of the American Heart Association (AHA). Her term begins July 1, 2013.

I am thrilled and honored to serve as the president of the AHA. It is an outstanding organization dedicated to building healthier lives, free of cardiovascular disease and stroke, said Jessup, who is also a member of the Penn Medicine Cardiovascular Institute. These goals are the same as those I have dedicated my professional life to, so this new role is a perfect fit.

Dr. Jessups focus throughout her career has been on the optimal management of patients with heart failure, including the appropriate selection of patients for heart transplant or ventricular assist devices (VADs). As medical director of the Penn Medicine Heart and Vascular Center, she works with a multi-disciplinary team of cardiologists, cardiac and vascular surgeons, nurse practitioners, and nurses to deliver collaborative, cutting-edge care to heart patients.

Dr. Jessup ascends to this position of national leadership at a critical moment in the field of cardiovascular disease. In doing so, she follows on the rich tradition of Penn Medicine in the nation's service, said Richard P. Shannon, MD, Frank Wister Thomas Professor of Medicine and chair, Department of Medicine at Penn. Her detailed understanding of the importance of discovery toward the betterment of the human condition will inform her tenure. Her experience as a clinician will insure that the voice of the patient burdened with heart disease will be heard above all else.

As a world renowned expert, Jessup has been an integral member of numerous guidelines committees aimed at directing optimal decisions and criteria regarding diagnosis, management, and treatment of patients with heart failure. A volunteer for more than 15 years, she was chairperson of the AHAs Committee on Scientific Sessions Program in 2009 and 2010, and chaired the committee that created the 2009 revision of the American College of Cardiology Foundation/American Heart Association Guidelines for the Management of Congestive Heart Failure.

She received her Bachelor of Arts degree from the University of Pennsylvania and her medical degree from Hahnemann Medical College. She completed her residency in Internal Medicine at Hahnemann University Hospital and a cardiovascular fellowship at the Hospital of the University of Pennsylvania.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Original post:

Mariell Jessup, MD, Penn Medicine Cardiologist, Becomes President of the American Heart Association


  1. Medicine